155 related articles for article (PubMed ID: 2185785)
21. Liposomes as antigen carriers and adjuvants in vivo.
Buiting AM; van Rooijen N; Claassen E
Res Immunol; 1992 Jun; 143(5):541-8; discussion 578-9. PubMed ID: 1439135
[No Abstract] [Full Text] [Related]
22. Resistance to intracellular infection in mice immunized with Toxoplasma vaccine and adjuvant.
Ruskin J; Remington JS
J Reticuloendothel Soc; 1971 May; 9(5):465-79. PubMed ID: 4997287
[No Abstract] [Full Text] [Related]
23. [The new vaccines and immunologic response (and II). The antigenic presentation. Adjuvants as inducers of inducer T-lymphocyte cell-mediated response].
Villarrubia VG; Calvo CG; Sada G
Med Clin (Barc); 1996 Jun; 107(5):185-96. PubMed ID: 8758679
[No Abstract] [Full Text] [Related]
24. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
Drane D; Gittleson C; Boyle J; Maraskovsky E
Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156
[TBL] [Abstract][Full Text] [Related]
25. Current status of immunological adjuvants.
Warren HS; Vogel FR; Chedid LA
Annu Rev Immunol; 1986; 4():369-88. PubMed ID: 2871847
[No Abstract] [Full Text] [Related]
26. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.
Watson DS; Endsley AN; Huang L
Vaccine; 2012 Mar; 30(13):2256-72. PubMed ID: 22306376
[TBL] [Abstract][Full Text] [Related]
27. Induction and direction of immune responses by vaccine adjuvants.
Schijns VE
Crit Rev Immunol; 2001; 21(1-3):75-85. PubMed ID: 11642615
[TBL] [Abstract][Full Text] [Related]
28. Use of liposomes as biodegradable and harmless adjuvants.
van Rooijen N; van Nieuwmegen R
Methods Enzymol; 1983; 93():83-95. PubMed ID: 6346015
[No Abstract] [Full Text] [Related]
29. Immunity in response to particulate antigen-delivery systems.
Storni T; Kündig TM; Senti G; Johansen P
Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
[TBL] [Abstract][Full Text] [Related]
30. New views on immunopotentiators in modern vaccines.
Schijns VE; Brewer JM
Expert Rev Vaccines; 2008 Sep; 7(7):877-9. PubMed ID: 18767938
[TBL] [Abstract][Full Text] [Related]
31. Cytokine-containing liposomes as vaccine adjuvants.
Lachman LB; Ozpolat B; Rao XM
Eur Cytokine Netw; 1996 Dec; 7(4):693-8. PubMed ID: 9010671
[TBL] [Abstract][Full Text] [Related]
32. Potentiation of the activity of mucosal vaccines by immunological adjuvants.
Dima VF; Balotescu C; Dima SV
Roum Arch Microbiol Immunol; 2000; 59(3):157-210. PubMed ID: 11850877
[No Abstract] [Full Text] [Related]
33. pH-sensitive liposomes as adjuvants for peptide antigens.
Chang JS; Choi MJ
Methods Enzymol; 2003; 373():127-36. PubMed ID: 14714401
[No Abstract] [Full Text] [Related]
34. Improving vaccine performance with adjuvants.
Vogel FR
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
[TBL] [Abstract][Full Text] [Related]
35. The role of the lymphatic system in vaccine trafficking and immune response.
Pal I; Ramsey JD
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):909-22. PubMed ID: 21683103
[TBL] [Abstract][Full Text] [Related]
36. Liposomes as oral adjuvants.
Michalek SM; Childers NK; Katz J; Denys FR; Berry AK; Eldridge JH; McGhee JR; Curtiss R
Curr Top Microbiol Immunol; 1989; 146():51-8. PubMed ID: 2659275
[TBL] [Abstract][Full Text] [Related]
37. Fully mobilizing host defense: building better vaccines.
Raychaudhuri S; Rock KL
Nat Biotechnol; 1998 Nov; 16(11):1025-31. PubMed ID: 9831030
[TBL] [Abstract][Full Text] [Related]
38. Vaccine entrapment in liposomes.
Gregoriadis G; McCormack B; Obrenovic M; Saffie R; Zadi B; Perrie Y
Methods; 1999 Sep; 19(1):156-62. PubMed ID: 10525452
[TBL] [Abstract][Full Text] [Related]
39. Need for new vaccine formulations and potential of particulate antigen and DNA delivery systems.
Friede M; Aguado MT
Adv Drug Deliv Rev; 2005 Jan; 57(3):325-31. PubMed ID: 15560944
[No Abstract] [Full Text] [Related]
40. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
Nordly P; Madsen HB; Nielsen HM; Foged C
Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
